Search

Your search keyword '"Hundsdörfer, Patrick"' showing total 70 results

Search Constraints

Start Over You searched for: Author "Hundsdörfer, Patrick" Remove constraint Author: "Hundsdörfer, Patrick" Database Unpaywall Remove constraint Database: Unpaywall
70 results on '"Hundsdörfer, Patrick"'

Search Results

1. Non-Syndromic and Syndromic Defects in Children with Extracranial Germ Cell Tumors: Data of 2610 Children Registered with the German MAKEI 96/MAHO 98 Registry Compared to the General Population

2. Supplementary Table 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

3. Supplementary Figure 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

4. Supplementary Figure 9 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

5. Supplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

6. Supplementary Figure 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

7. Supplementary Figure 10 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

8. Supplementary Figure 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

9. Supplementary Figure 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

10. Supplementary Figure 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

11. Supplementary Figure 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

12. Supplementary Figure 8 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

13. Supplementary Figure 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

14. Supplementary Table 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

15. Supplementary Figure 12 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

16. Supplementary Table 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

17. Supplementary Figure 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

18. Supplementary Table 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

19. Supplementary Table 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

20. Supplementary Figure 8 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

21. Data from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

22. Supplementary Figure 7 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

23. Supplementary Figure 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

24. Supplementary Table 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

25. Supplementary Table 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

26. Supplementary Table 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

27. Supplementary Table 4 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

28. Supplementary Figure 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

29. Supplementary Table 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

30. Supplementary Figure 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

31. Supplementary Figure 13 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

32. Supplementary Figure 10 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

33. Supplementary Figure 3 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

34. Supplementary Figure 9 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

35. Supplementary Figure 13 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

36. Supplementary Figure 12 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

37. Supplementary Table 2 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

38. Data from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

39. Supplementary Figure 11 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

40. Supplementary Figure 1 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

41. Supplementary Table 5 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

42. Supplementary Table 6 from Elimusertib has Antitumor Activity in Preclinical Patient-Derived Pediatric Solid Tumor Models

43. Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

44. Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

45. Supplementary Data from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

46. Supplementary Data from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

47. Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

48. Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

49. Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

50. Supplementary Figure from Targeted Analysis of Cell-free Circulating Tumor DNA is Suitable for Early Relapse and Actionable Target Detection in Patients with Neuroblastoma

Catalog

Books, media, physical & digital resources